Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Fig. 3

Kaplan–Meier estimates for OS in the axitinib- and placebo-titration arms. (a) Stratified by time from histopathological diagnosis to treatment, (b) stratified by baseline haemoglobin level, and (c) stratified by number of metastatic sites. Abbreviations: CI confidence interval, LLN lower limit of normal, mOS median overall survival, NE not estimable, OS overall survival

Back to article page